Q: I am wondering why you think biosyent hasn't moved in the past six months, depute excellent growth in revenue and earnings, ROE above 40%, no debt, and new products coming on stream. Any thoughts?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: What do you think about the management changes announced today? Is it a sign of accounting manipulation of any sort?
Thanks
Thanks
Q: Happy New Year Peter and staff. Nobilis shareholders are involved in a law suit in U.S. Do you feel I should get out now or wait it out. There is no loss now but it can be so messy! Thanks your you expert insight. Rossana
Q: Hi folks,can u please comment on re-statement of financials for Nhc/t.Is this good or bad,and long term,is this stock a buy,hold or total avoid. Thanks as always
Q: Happy New Year to the 5i Team,
I found your answer to the question regarding PHM`s year end results to be clear, factual, but guarded; understandable, considering the dramatic start to this morning`s opening of the North American markets. By the end of the day, the stock went up 25% with huge volume. I am currently with BMO Investorline, who are on record as stating that ``There are currently no news headlines for this security`. Without overstating the obvious, would you be able to offer any further observations or feedback after today`s results, on an otherwise gloomy day? I find it hard to believe that there has not been more interest shown by other members in this event. Thank you as always. Rick
I found your answer to the question regarding PHM`s year end results to be clear, factual, but guarded; understandable, considering the dramatic start to this morning`s opening of the North American markets. By the end of the day, the stock went up 25% with huge volume. I am currently with BMO Investorline, who are on record as stating that ``There are currently no news headlines for this security`. Without overstating the obvious, would you be able to offer any further observations or feedback after today`s results, on an otherwise gloomy day? I find it hard to believe that there has not been more interest shown by other members in this event. Thank you as always. Rick
Q: Hi Guys,
Could you comment on PHM's stock based compensation for 2015 of $9,162,835.
Is this reasonable and what holds in the future for this?
Thanks
John
Could you comment on PHM's stock based compensation for 2015 of $9,162,835.
Is this reasonable and what holds in the future for this?
Thanks
John
Q: Happy New Year to all. Could have your opinion of the merger of agn and pfe. and a 1 year outlook for agn.
Q: Is Cipher a good deal at it's current price? Can you update us on your view of this company?
Q: Hello 5i!
Thinking of adding PHM at these low levels to my portfolio, what allocation is reasonable within a diversified portfolio, I am a long term investor, well diversified portfolio and can handle risk.
Thanks!
Thinking of adding PHM at these low levels to my portfolio, what allocation is reasonable within a diversified portfolio, I am a long term investor, well diversified portfolio and can handle risk.
Thanks!
Q: Could you please comment on $CRH for a medium term hold, thanks Valter
Q: Hi
My holdings in VRX are near my purchase price after the bounce back from the short attack. I'm concerned about headwinds from the issues around the short and wonder if it would make sense to switch to one of CXR, CRH or GUD.Thanks Keith
My holdings in VRX are near my purchase price after the bounce back from the short attack. I'm concerned about headwinds from the issues around the short and wonder if it would make sense to switch to one of CXR, CRH or GUD.Thanks Keith
Q: Seasons Greetings!!!
Your last comment on Horizon Pharma was Feb/15. Could I have your current opinion please?
Thanks
Dave
Your last comment on Horizon Pharma was Feb/15. Could I have your current opinion please?
Thanks
Dave
Q: The latest update on NHC delay in filing their financial statements seems to include a new issues of concern including accounting for warrants and option issued in the past, compensation matters and even calculations of fully diluted shares. A month after missing their filing date, there doesn't seem to be much progress and instead a number of new issues. Do you think the red flags are waving?
Q: My question pertains to the loan Gud made to Extenway in June 2015. After looking at the Extenway financials I am perplexed to find a reason why GUD management would have entered into such an agreement in the first place. If their loan portfolio is anywhere close to this transaction I think there is a serious problem. Could I get your thoughts on this one.
Q: Now that they have started phase 1 trials with md Anderson, do you have any change to your view on the company??
Q: What do you think of their recent revenue update?
Many thanks
Many thanks
Q: Do you think the latest news in their drug approval is any reason to start a small speculative position.
Thanks
Thanks
Q: Hi guys,
Any news why Ten Peaks Coffee is hitting an all-time high on a 9% move? All I could find was a dividend announcement which would hardly be a catalyst for such a move.
Any news why Ten Peaks Coffee is hitting an all-time high on a 9% move? All I could find was a dividend announcement which would hardly be a catalyst for such a move.
Q: Today, Acasti (APO) announced positive feedback from the US FDA and, as a result, its shares jumped about 50%. However, the share price of NTP, which owns almost 50% of APO, rose less than 10%. I would have expected an approx. 25% increase for NTP. Is this a good arbitrage opportunity?
Q: At this time, the only healthcare stock I hold is a 3% weighting in CXR. I would like to add to this sector. My question is, after today's developments with Valeant, would you recommend initiating a small position? Any other suggestions are most welcome.
Thank you
Thank you